Xeltis
Develops restorative cardiovascular implants designed to create artificial vessels and valves that are replaced by patients’ own tissue.
Overview
Xeltis is a Dutch-US medtech company developing artificial blood vessels and heart valves intended to be replaced over time by patients’ own tissue. Its work targets cardiovascular care, where implant durability and biological integration are key clinical needs. The company’s differentiator is a restorative approach to implants rather than permanent artificial replacements. Xeltis raised €20.5 million, reported as about $21 million, in an undisclosed 2026 round to advance its artificial vessels and valves.
Funding History
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue
Frequently Asked Questions
- How much has Xeltis raised in total?
- Xeltis has raised a total of $21M across 1 funding round.
- What does Xeltis do?
- Xeltis is a Dutch-US medtech company developing artificial blood vessels and heart valves intended to be replaced over time by patients’ own tissue. Its work targets cardiovascular care, where implant durability and biological integration are key clinical needs. The company’s differentiator is a restorative approach to implants rather than permanent artificial replacements. Xeltis raised €20.5 million, reported as about $21 million, in an undisclosed 2026 round to advance its artificial vessels and valves.
- Where is Xeltis headquartered?
- Xeltis is headquartered in Eindhoven, Netherlands.
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.